Cave rescue

Median Technologies to Speak at the Radiological Society of North America (RSNA) 2022 Annual Meeting, Nov. 27 - Dec 1, Chicago, IL, USA, With Three Presentations

Retrieved on: 
Tuesday, November 22, 2022
Radiology, Biotechnology, Oncology, Health, Artificial Intelligence, Medical Devices, Technology, Other Health, AI, BPI, Patient, Cancer, Cave rescue, Exhibition, SME, Artificial intelligence, Diagnosis

Medians teams will be available at booth #4849, Level 3 South Hall (AI showcase) for the duration of the industry exhibition (Nov 27- 30).

Key Points: 
  • Medians teams will be available at booth #4849, Level 3 South Hall (AI showcase) for the duration of the industry exhibition (Nov 27- 30).
  • About Median Technologies: Median Technologies provides innovative imaging solutions and services to advance healthcare for everyone.
  • This is how we are helping to create a healthier world.
  • Median is eligible for the French SME equity savings plan scheme (PEA-PME), is part of the Enternext PEA-PME 150 index and has been awarded the Euronext European Rising Tech label.

Median Technologies Announces Its 2022 Half-year Results and Revenues for the Third Quarter

Retrieved on: 
Thursday, October 20, 2022
Biotechnology, Medical Devices, Other Health, Health, Oncology, AMF, IFRS, Diagnosis, Lists of diseases, Cave rescue, Patient, Research, Investment, EIB, BPI, Artificial intelligence, Intellectual property, Forward-looking statement, Solution, Cancer, SME, Cryptocurrency, Security (finance), Risk management

The increase in revenues and the margin generated by the iCRO business helped reduce the impact of investments in iBiopsy on operating result.

Key Points: 
  • The increase in revenues and the margin generated by the iCRO business helped reduce the impact of investments in iBiopsy on operating result.
  • This valuation has been significantly impacted by changes in the share price since the issue of these warrants.
  • Median Technologies does not undertake to update any forward-looking information or statements, subject to applicable regulations, in particular Articles 223-1 et seq.
  • About Median Technologies: About Median Technologies: Median Technologies provides innovative imaging solutions and services to advance healthcare for everyone.

A Transformational Year: ImaginAb expands Pipeline to include Radiopharmaceutical Therapies, enters Multiple Partnerships, and Drives Forward Development of Investigational CD8 ImmunoPET Agent

Retrieved on: 
Tuesday, October 4, 2022
CD8, Society for Immunotherapy of Cancer, RPT, Prognosis, GMA, Society, GMP, AstraZeneca, Boehringer Ingelheim, Medication, Technology, BOT, Research, IND, Biologics license application, Memorial Sloan Kettering Cancer Center, Immunotherapy, Cave rescue, MSKCC, Atezolizumab, Patient, Papillary renal cell carcinoma, COVID-19, Phase II, Roche, CRO, PET, University of California, Davis, Partnership, BLA, Pfizer, Inclusion body myositis, SITC, United Kingdom, IPredict, Radiopharmaceutical, University, IBM, Melanoma, Data analysis, CMO, Fine chemical, Pharmaceutical industry, Medical imaging, Biotechnology

ImaginAb continues the clinical development of CD8 ImmunoPET with a target to file a Biologics License Application (BLA) submission in the next two years.

Key Points: 
  • ImaginAb continues the clinical development of CD8 ImmunoPET with a target to file a Biologics License Application (BLA) submission in the next two years.
  • In August 2021, ImaginAb completed its Phase I IBM study showing utility of CD8 ImmunoPET to detect disease pathology in Inclusion Body Myositis (IBM) patients.
  • ImaginAb formally launched its Phase IIb 'iPREDICT' study to measure CD8 ImmunoPET imaging predictivity and prognosis, building on the data from its promising Phase IIa 'BOT' study.
  • These GMA agreements include:
    PharmaLogic, the fastest growing radiopharmaceutical manufacturer in North America, to manufacture and distribute CD8 ImmunoPET for ImaginAb.

A Transformational Year: ImaginAb expands Pipeline to include Radiopharmaceutical Therapies, enters Multiple Partnerships, and Drives Forward Development of Investigational CD8 ImmunoPET Agent

Retrieved on: 
Tuesday, October 4, 2022
CD8, Society for Immunotherapy of Cancer, RPT, Prognosis, GMA, Society, GMP, AstraZeneca, Boehringer Ingelheim, Medication, Technology, BOT, Research, IND, Biologics license application, Memorial Sloan Kettering Cancer Center, Immunotherapy, Cave rescue, MSKCC, Atezolizumab, Patient, Papillary renal cell carcinoma, COVID-19, Phase II, Roche, CRO, PET, University of California, Davis, Partnership, BLA, Pfizer, Inclusion body myositis, SITC, United Kingdom, IPredict, Radiopharmaceutical, University, IBM, Melanoma, Data analysis, CMO, Fine chemical, Pharmaceutical industry, Medical imaging, Biotechnology

ImaginAb continues the clinical development of CD8 ImmunoPET with a target to file a Biologics License Application (BLA) submission in the next two years.

Key Points: 
  • ImaginAb continues the clinical development of CD8 ImmunoPET with a target to file a Biologics License Application (BLA) submission in the next two years.
  • In August 2021, ImaginAb completed its Phase I IBM study showing utility of CD8 ImmunoPET to detect disease pathology in Inclusion Body Myositis (IBM) patients.
  • ImaginAb formally launched its Phase IIb 'iPREDICT' study to measure CD8 ImmunoPET imaging predictivity and prognosis, building on the data from its promising Phase IIa 'BOT' study.
  • These GMA agreements include:
    PharmaLogic, the fastest growing radiopharmaceutical manufacturer in North America, to manufacture and distribute CD8 ImmunoPET for ImaginAb.

Median Technologies Announces Formation of Clinical Advisory Board for iBiopsy® Lung Cancer Screening

Retrieved on: 
Monday, October 3, 2022
Biotechnology, Medical Devices, Other Health, Health, Oncology, LCS, Liver cancer, University of Pennsylvania Health System, Hospital, Journal of Thoracic Oncology, Precision medicine, Knowledge, Data science, HCC, Icahn School of Medicine at Mount Sinai, Radiology, Technology, SME, Division, Intervention, Mount Auburn Hospital, Associate professor, Cave rescue, NASH, View, Lung cancer, Software, University of Insubria, Hospital of the University of Pennsylvania, CCO, Cancer, Patient, Lung cancer screening, Diagnosis, University, Faculty, Clinical research, CAB, Prognosis, Physician, Critical care, Lists of diseases, BPI, Cirrhosis, Associate, Department, COO, Section, DS, Solution, Oncology, Medical device, Harvard Medical School, Artificial intelligence, Medical imaging, Medicine, Mount Sinai Morningside

Median Technologies (Paris:ALMDT) announced today the formation of their Clinical Advisory Board (CAB) for iBiopsy Lung Cancer Screening.

Key Points: 
  • Median Technologies (Paris:ALMDT) announced today the formation of their Clinical Advisory Board (CAB) for iBiopsy Lung Cancer Screening.
  • I am pleased and honored to be working with this team of distinguished and highly accomplished clinicians, whos wealth of knowledge and experience will help Median deliver on optimizing the Lung Cancer Screening routine and saving patient lives.
  • iBiopsy currently focuses on lung cancer, liver cancer (HCC) and liver fibrosis (NASH).
  • About Median Technologies: Median Technologies provides innovative imaging solutions and services to advance healthcare for everyone.

Median Technologies to Participate in the 2022 ESMO Congress, Sep 9 – 13, 2022, Paris, France, With Two Scientific Posters on iCRO and iBiopsy®

Retrieved on: 
Tuesday, September 6, 2022
Biotechnology, Technology, Health, Pharmaceutical, Oncology, Health Technology, Medical Devices, Research, Artificial Intelligence, Science, Clinical Trials, Cave rescue, European Society for Medical Oncology, Computer, Bent Image Lab, Lists of diseases, View, BPI, Exhibition, Artificial intelligence, Solution, ESMO, Diagnosis, SME, Lung cancer, Company, Intelligence, LCS, Oncology, Cancer, CEST, Congress, Technology, Industry, Drug development, Patient, Flour, Medical imaging

Median Technologies (ALMDT) (Paris:ALMDT) announced today that the Company will be participating in the 2022 ESMO (European Society for Medical Oncology) Congress, to be held in Paris, France, September 9-13 (venue: Paris Expo Porte de Versailles).

Key Points: 
  • Median Technologies (ALMDT) (Paris:ALMDT) announced today that the Company will be participating in the 2022 ESMO (European Society for Medical Oncology) Congress, to be held in Paris, France, September 9-13 (venue: Paris Expo Porte de Versailles).
  • The Company will present two scientific posters.
  • Daily presentation sessions on Imaging Lab are planned at 3:00 pm CEST at booth.
  • More about the ESMO congress: https://www.esmo.org/meetings/esmo-congress-2022
    About Median Technologies: Median Technologies provides innovative imaging solutions and services to advance healthcare for everyone.

Imaging Endpoints Appoints Jatinder Kaur as Chief Operating Officer

Retrieved on: 
Wednesday, August 17, 2022
Cave rescue, IE, Industry, CD8, Compliance, Technology, Growth, CRO, Clinical trial, CRA, Leadership, Clinical, Reward, Company, Innovation, COO, SMIL, Artificial intelligence, Publication, Jatinder Mauhar, Data management, Clinical endpoint, Cros, Bureau of Oceans and International Environmental and Scientific Affairs, Information technology, Medical imaging, Cure

SCOTTSDALE, Ariz., Aug. 17, 2022 /PRNewswire/ -- Imaging Endpoints (IE), based in Scottsdale, Arizona with eight offices in six countries, announced today the promotion of Jatinder Kaur to Chief Operating Officer (COO). Jatinder most recently served as Executive Vice President of Operations at Imaging Endpoints, and has been with the Company for over eight years. She has led the company's global expansion, building IE into one of the largest imaging CROs (iCROs) globally and the largest oncology-focused iCRO.

Key Points: 
  • SCOTTSDALE, Ariz., Aug. 17, 2022 /PRNewswire/ -- Imaging Endpoints (IE), based in Scottsdale, Arizona with eight offices in six countries, announced today the promotion of Jatinder Kaur to Chief Operating Officer (COO).Jatinder most recently served as Executive Vice President of Operations at Imaging Endpoints, and has been with the Company for over eight years.
  • Imaging Endpoints announced today the promotion of Jatinder Kaur to Chief Operating Officer.
  • Under the leadership and direction of Jatinder Kaur, Imaging Endpoints is realizing its vision to Connect Imaging to the Cure() by customizing imaging for each clinical trial to optimize the opportunity to demonstrate efficacy.
  • Imaging Endpoints (IE) is an imaging CRO that is passionately focused on its vision to Connect Imaging to the Cure.

Median Technologies: Financial Communication Schedule for the Second Half of 2022

Retrieved on: 
Monday, July 25, 2022
Radiology, Biotechnology, Hardware, Health, Medical Devices, Technology, Other Technology, Other Health, Cave rescue, Artificial intelligence, SME, Diagnosis, View, Solution, Lists of diseases, BPI, Cancer, Patient

About Median Technologies: About Median Technologies: Median Technologies provides innovative imaging solutions and services to advance healthcare for everyone.

Key Points: 
  • About Median Technologies: About Median Technologies: Median Technologies provides innovative imaging solutions and services to advance healthcare for everyone.
  • This is how we are helping to create a healthier world.
  • Founded in 2002, based in Sophia-Antipolis, France, with a subsidiary in the US and another one in Shanghai, Median has received the label Innovative company by the BPI and is listed on Euronext Growth market (Paris).
  • Median is eligible for the French SME equity savings plan scheme (PEA-PME), is part of the Enternext PEA-PME 150 index and has been awarded the Euronext European Rising Tech label.

Median Technologies Communicates Its Business Indicators for the Second Quarter of 2022

Retrieved on: 
Monday, July 11, 2022
Software, Biometrics, Biotechnology, Health, Medical Devices, Data Management, Health Technology, Technology, Collection, Solution, FDA, COVID-19, CEO, BPI, Disease, LCS, AI, Medical device, Intellectual property, Marketing, Lung cancer, Bent Image Lab, SME, Element, Artificial intelligence, Forward-looking statement, Software, Cade, Cave rescue, ASCO, Mission statement, Cancer, Review, Federal Food, Drug, and Cosmetic Act, Data mining, Group, Research, Patient, Lists of diseases, Growth, Technology, Diagnosis, Renewable energy, Fine chemical, Medical imaging, Median

Median Technologies (ALMDT:PA) (Paris:ALMDT) today announces its business indicators for the first half of 2022.

Key Points: 
  • Median Technologies (ALMDT:PA) (Paris:ALMDT) today announces its business indicators for the first half of 2022.
  • Following record revenues in Q1 2022 of 5.7 million, Median Technologies continued its strong growth with Q2 2022 revenues of 7.0 million, which is a 43% increase versus Q2 2021 (4.9 million).
  • The growth momentum of our business continued during the second quarter of 2022, with record quarterly revenues, up 43% versus the same period year ago.
  • About Median Technologies: About Median Technologies: Median Technologies provides innovative imaging solutions and services to advance healthcare for everyone.

Median Technologies to Participate in the 2022 European Congress of Radiology (ECR), July 13 – 17, 2022, Vienna, Austria, with Two Presentations on iBiopsy®

Retrieved on: 
Friday, July 8, 2022
Technology, Medical Devices, Health Technology, Software, Other Health, Biotechnology, Radiology, Health, Data Management, Oncology, Diagnosis, Cirrhosis, FDA, European Society of Radiology, NASH, Patient, Research, Precision medicine, Informatics, Technology, HCC, LCS, Liver cancer, Company, ESR, Industry, Data science, Lung cancer, RPS, DS, Prognosis, Cancer, PACS, Software, Lists of diseases, ECR, SME, Artificial intelligence, Cave rescue, Solution, Congress, Cade, Medical device, Knowledge, BPI, Medical imaging, Radiology, European

Median Technologies (ALMDT) (Paris:ALMDT) announced today that the Company will be participating in the 2022 European Congress of Radiology (ECR), to be held in Vienna, Austria, July 13-17.

Key Points: 
  • Median Technologies (ALMDT) (Paris:ALMDT) announced today that the Company will be participating in the 2022 European Congress of Radiology (ECR), to be held in Vienna, Austria, July 13-17.
  • The European Congress of Radiology (ECR) organized by the European Society of Radiology (ESR) is the premier European event in radiology and the second largest in the world.
  • The congress conveys more than 20,000 with a split of more than 10,000 professional delegates (radiologists, technologists etc.
  • About Median Technologies: Median Technologies provides innovative imaging solutions and services to advance healthcare for everyone.